Driving the next generation of CAR-T therapy @Novartis
Driving the next generation of CAR-T therapy  @Novartis
Uploaded October 2022 | Updated November 2026, 3 hours ago
By extracting human immune cells and genetically reprogramming them to hunt cancer cells, CAR-T therapy changed the treatment paradigm for patients with certain blood cancers.

How do we drive forward the next generation of this potentially transformative technology? At Novartis, we’re developing our T-Charge platform as a foundation to build future CAR-T therapies that can address more of the challenges that cancers pose.

Learn more: bit.ly/3gIGxEZ

©2022 Novartis AG
Driving the next generation of CAR-T therapyNext Generation Scientist 2023Living with CML: A Patient and Doctor Reflect on Care, Progress and HopeThe Future of Health: Unlocking the power of data to improve urban healthBring your whole self to work at NovartisHow many types of cancer can you name?Keeping a persistent killer on the runNext Generation Scientist 2024S is for Screening webinarInternational Women’s Day 2023The role of digitization and AI in finding new medicinesThe global state of heart disease
Novartis |

Driving the next generation of CAR-T therapy

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER